retatrutide obesity clinical trial results vs Tirzepatide (2026): Differences in Weight Loss, Metabol – Revolution Health & Wellness This data from Phase 3

Its dual mechanism delivers superior results compared to single-agonist alternatives, and its established safety profile provides reassurance for patients and healthcare providers

doi: 10.4103/ijd.IJD_137_18 31

The absence of the stomach is a historical status: it informs the reason for the visit but does not define it

To maintain results, some patients may require ongoing treatment with maintenance injections at regular intervals

Are there signs of tolerance or diminishing returns

Research has demonstrated that GHK-type peptides can downregulate transforming growth factor-beta 1 (TGF-1), a cytokine implicated in premature follicle regression and the shift from anagen to catagen